tbuckley/cabot-search huggingface dataset:
Extracellular Vesicle-Encapsulated microRNAs as Novel Biomarkers of Lung Health
Authors: Christina M. Eckhardt, Simone Gambazza, Tessa R. Bloomquist, Peter De Hoff, Aishwarya Vuppala, Pantel S. Vokonas, Augusto A. Litonjua, David Sparrow, Faruque Parvez, Louise C. Laurent, Joel Schwartz, Andrea A. Baccarelli, Haotian Wu
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Early detection of respiratory diseases is critical to facilitate delivery of disease-modifying interventions. Extracellular vesicle-enriched microRNAs (EV-miRNAs) may represent reliable markers of early lung injury.
Awards, Appointments, Announcements
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Awards, Appointments, Announcements Get access JNCI: Journal of the National Cancer Institute, Volume 87, Issue 16, 16 August 1995, Pages 1215–1216, https://doi.org/10.1093/jnci/87.16.1215 Published: 16 August 1995
Error in Medicine
Authors: Lucian L. Leape
Journal: JAMA (1994)

FOR YEARS, medical and nursing students have been taught Florence Nightingale's dictum—first, do no harm.<sup>1</sup>Yet evidence from a number of sources, reported over several decades, indicates that a substantial number of patients suffer treatment-caused injuries while in the hospital.<sup>2-6</sup> In 1964 Schimmel<sup>2</sup>reported that 20% of patients admitted to a university hospital medical service suffered iatrogenic injury and that 20% of those injuries were serious or fatal. Steel et al<sup>3</sup>found that 36% of patients admitted to a university medical service in a teaching hospital suffered an iatrogenic event, of which 25% were serious or life threatening. More than half of the injuries were related to use of medication.<sup>3</sup>In 1991 Bedell et al<sup>4</sup>reported the results of an analysis of cardiac arrests at a teaching hospital. They found that 64% were preventable. Again, inappropriate use of drugs was the leading cause of
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Authors: Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Journal: Annals of the Rheumatic Diseases (2022)

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still’s disease, Castleman’s disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
Population study on diagnosis, treatment and outcomes of critically ill patients with tuberculosis (2008–2018)
Authors: Christina So, Lowell Ling, Wai Tat Wong, Jack Zhenhe Zhang, Chun Ming Ho, Pauline Yeung Ng, Hoi Ping Shum, Alwin Wai Tak Yeung, Kai Cheuk Sin, Jacky Chan, Ka Fai Au, Ting Liong, Eunise Ho, Fu Loi Chow, Laptin Ho, Kai Man Chan, Gavin Matthew Joynt
Journal: Thorax (2022)

Tuberculosis (TB) is a preventable and curable disease, but mortality remains high among those who develop sepsis and critical illness from TB.This was a population-based, multicentre retrospective cohort study of patients admitted to all 15 publicly funded Hong Kong adult intensive care units (ICUs) between 1 April 2008 and 31 March 2019. 940 adult critically ill patients with at least one positive Mycobacterium tuberculosis (MTB) culture were identified out of 133 858 ICU admissions. Generalised linear modelling was used to determine the impact of delay in TB treatment on hospital mortality. Trend of annual Acute Physiology and Chronic Health Evaluation (APACHE) IV-adjusted standardised mortality ratio (SMR) over the 11-year period was analysed by Mann-Kendall's trend test.ICU and hospital mortality were 24.7% (232/940) and 41.1% (386/940), respectively. Of those who died in the ICU, 22.8% (53/232) never received antituberculosis drugs. SMR for ICU patients with TB remained unchanged over the study period (Kendall's τb=0.37, p=0.876). After adjustment for age, Charlson comorbidity index, APACHE IV, albumin, vasopressors, mechanical ventilation and renal replacement therapy, delayed TB treatment was directly associated with hospital mortality. In 302/940 (32.1%) of patients, TB could only be established from MTB cultures alone as Ziehl-Neelsen staining or PCR was either not performed or negative. Among this group, only 31.1% (94/302) had concurrent MTB PCR performed.Survival of ICU patients with TB has not improved over the last decade and mortality remains high. Delay in TB treatment was associated with higher hospital mortality. Use of MTB PCR may improve diagnostic yield and facilitate early treatment.
Progress Toward Measles Elimination — South-East Asia Region, 2003–2020
Authors: Sudhir Khanal, Ahmed M. Kassem, Sunil Bahl, Liyanage Jayantha, Lucky Sangal, Mohammad Sharfuzzaman, Anindya Sekhar Bose, Sebastien Antoni, Deblina Datta, James P. Alexander
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

and Timor-Leste
COVID-19 Outbreaks and Mortality Among Public Transportation Workers — California, January 2020–May 2022
Authors: Amy Heinzerling, Ximena P. Vergara, Elisabeth Gebreegziabher, John Beckman, Jessie Wong, Alyssa Nguyen, Sana Khan, Matt Frederick, David Bui, Elena Chan, Kathryn Gibb, Andrea Rodriguez, Seema Jain, Kristin J. Cummings
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Work-related factors can contribute to risk for exposure to and infection with SARS-CoV-2, the virus that causes COVID-19, and subsequent COVID-19-attributable outcomes, including death.Comparing COVID-19 metrics across industries can help identify workers at highest risk.Elevated COVID-19 mortality rates have been reported among all transportation workers, as well as specifically in public transportation industries (1-3).The California Department of Public Health (CDPH) calculated public transportation industry-specific COVID-19 outbreak incidence during January 2020-May 2022 and analyzed all laboratory-confirmed COVID-19 deaths among working-age adults in California to calculate public transportation industry-specific mortality rates during the same period.Overall, 340 confirmed COVID-19 outbreaks, 5,641 outbreak-associated cases, and 537 COVID-19-associated deaths were identified among California public transportation industries.Outbreak incidence was 5.2 times as high (129.1 outbreaks per 1,000 establishments) in the bus and urban transit industry and 3.6 times as high in the air transportation industry (87.7) as in all California industries combined (24.7).Mortality rates were 2.1 times as high (237.4deaths per 100,000 workers) in transportation support services and 1.8 times as high (211.5) in the bus and urban transit industry as in all industries combined (114.4).Workers in public transportation industries are at higher risk for COVID-19 workplace outbreaks and mortality than the general worker population in California and should be prioritized for COVID-19 prevention strategies, including vaccination and enhanced workplace protection measures.This report assessed confirmed COVID-19 outbreaks in California workplaces that began during January 1, 2020-May 26, 2022, and were reported to CDPH as of June 27, 2022.Confirmed COVID-19 outbreaks were defined as the occurrence of three or more probable or confirmed COVID-19 cases within a 14-day period among persons who are epidemiologically linked in the setting, are from different households, and are not identified as close contacts of one another in any other case investigation (4).Since January 1, 2021, California employers have been required to report workplace clusters of three or more COVID-19 cases within 14 days to their local health department (LHD); previously, outbreak reporting requirements varied by setting and jurisdiction.LHDs report confirmed COVID-19 outbreaks and the number of outbreak-associated cases, which might include workers and nonworkers, to CDPH.
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Authors: Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
Journal: Liver Cancer (2017)

Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading (≤-2.60 = grade 1, greater than -2.60 to ≤-1.39 = grade 2, greater than -1.39 = grade 3) as well as clinical features and prognosis (Japan Integrated Staging [JIS], modified JIS, ALBI-TNM [ALBI-T] score) were retrospectively investigated. Results: For prediction of liver damage A, the values for sensitivity and specificity, positive predictive and negative predictive values, and positive and negative likelihood ratios of ALBI-1 and Child-Pugh A were similar among the 2 groups. Akaike information criterion results showed that prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score (22,291.8/21,989.4, 22,379.6/22,076.0, 22,392.1/22,075.1, respectively). The cutoff values for ALBI score for indocyanine green retention rate at 15 min (ICG-R15) &lt;10, &lt;20, and &lt;30% were -2.623 (area under the curve [AUC]: 0.798), -2.470 (AUC: 0.791), and -2.222 (AUC: 0.843), respectively. The distribution of ICG-R15 (&lt;10%, 10 to &lt;20%, 20 to &lt;30%, and ≥30%) for ALBI grade 1 was similar to that for liver damage A. There were only small differences with regard to therapeutic selection with the Japanese HCC treatment algorithm between liver damage and ALBI grade. Conclusion: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making.
Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study
Authors: Catherine Hyams, Robert Challen, Elizabeth Begier, Jo Southern, Jade King, Anna Morley, Zsuzsa Szasz-Benczur, Maria Garcia Gonzalez, Jane Kinney, James Campling, Sharon Gray, Jennifer Oliver, Robin Hubler, Srinivas Valluri, Andrew Vyse, John M. McLaughlin, Gillian Ellsbury, Nick A. Maskell, Bradford D. Gessner, Leon Danon, Adam Finn, Amelia Langdon, Anabella Turner, Anya Mattocks, Bethany Osborne, Charli Grimes, Claire Mitchell, David Adegbite, Emma Bridgeman, Emma Scott, Fiona Perkins, Francesca Bayley, Gabriella Ruffino, Gabriella Valentine, Grace Tilzey, Johanna Kellett Wright, Julia Brzezinska, Julie Cloake, Katarina Milutinovic, Kate Helliker, Katie Maughan, Kazminder Fox, Konstantina Minou, Lana Ward, Leah Fleming, Leigh Morrison, Lily Smart, Louise Wright, Lucy Grimwood, Maddalena Bellavia, Madeleine Clout, Marianne Vasquez, Milo Jeenes-Flanagan, Natalie Chang, Niall Grace, Nicola Manning, Oliver Griffiths, Pip Croxford, Peter Sequenza, Rajeka Lazarus, Rhian Walters, Robin Marlow, Robyn Heath, Rupert Antico, Sandi Nammuni Arachchge, Seevakumar Suppiah, Taslima Mona, Tawassal Riaz, Vicki Mackay, Zandile Maseko, Zoe Taylor, Zsolt Friedrich
Journal: The Lancet Regional Health - Europe (2022)
Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label, randomised controlled trial
Authors: Rena C Patel, Patrick Oyaro, Katherine K Thomas, James Wagude, Irene Mukui, Evelyn Brown, Shukri A Hassan, Eunice Kinywa, Frederick Oluoch, Francesca Odhiambo, Boaz Oyaro, Leonard Kingwara, Enericah Karauki, Nashon Yongo, Lindah Otieno, Grace C John-Stewart, Lisa L Abuogi
Journal: The Lancet Child & Adolescent Health (2022)
Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities
Authors: Kenneth Offit, Catherine M. Sharkey, Dina Green, Xiaohan Wu, Magan Trottier, Jada G. Hamilton, Michael F. Walsh, Sita Dandiker, Sami Belhadj, Steven M. Lipkin, Thelma Alessandra Sugrañes, Michele Caggana, Zsofia K. Stadler
Journal: Journal of Clinical Oncology (2022)

Cancer predictive or diagnostic assays, offered as Laboratory-Developed Tests (LDTs), have been subject to regulatory authority and enforcement discretion by the US Food and Drug Administration. Many LDTs enter the market without US Food and Drug Administration or any regulatory review. The Centers for Medicare &amp; Medicaid Services under the Clinical Laboratory Improvement Amendments focuses on analytic performance, but has limited oversight of the quality or utility of LDTs, including whether patients have been harmed as a result of their use. Increasingly, LDTs for cancer risk or early detection have been marketed directly to consumers, with many LDT developers depicting these tests, requested by patients but ordered by personal or company-associated physicians, as procedures falling under the practice of medicine. This patchwork of regulation and enforcement uncertainty regarding LDTs and public concerns about accuracy of tests given emergency authorization during the COVID-19 pandemic led to the Verifying Accurate Leading-edge IVCT (in vitro clinical test) Development Act of 2021. This pending federal legislation represents an opportunity to harmonize regulatory policies and address growing concerns over quality, utility, and safety of LDTs for cancer genomics, including tests marketed directly to consumers. We review here questions regarding the potential benefits and harms of some cancer-related LDTs for cancer risk and presymptomatic molecular diagnosis, increasingly marketed to oncologists or directly to the worried well. We offer specific proposals to strengthen oversight of the accuracy and clinical utility of cancer genetic testing to ensure public safety.
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Authors: Justin C. Brown, Chao Ma, Qian Shi, Charles S. Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Felix Couture, Philip Kuebler, Pankaj Kumar, DeQuincy Lewis, Benjamin Tan, Smitha Krishnamurthi, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt
Journal: Journal of Clinical Oncology (2022)

To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer.
Effectiveness of Laser Refractive Surgery to Address Anisometropic Amblyogenic Refractive Error in Children
Authors: Kara M. Cavuoto, Melinda Y. Chang, Gena Heidary, David G. Morrison, Rupal H. Trivedi, Gil Binenbaum, Stephen J. Kim, Stacy L. Pineles
Journal: Ophthalmology (2022)
Covid-19: Increased risk of some neurological and psychiatric disorders remains two years after infection, study finds
Authors: Jacqui Wise
Journal: BMJ (2022)

Covid-19: Increased risk of some neurological and psychiatric disorders remains two years after infection, study finds Jacqui WiseDisorders such as psychosis, dementia, seizures, and "brain fog" remain more common for as much as two years after covid-19 infection than after other respiratory infections, a large follow-up study has found.
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease
Authors: Matthew T. Rocco, Asad S. Akhter, Debra J. Ehrlich, Gretchen C. Scott, Codrin Lungu, Vikas Munjal, Anthony Aquino, Russell R. Lonser, Massimo S. Fiandaca, Mark Hallett, John D. Heiss, Krystof S. Bankiewicz
Journal: Molecular Therapy (2022)

Direct putaminal infusion of adeno-associated virus vector (serotype 2) (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene was studied in a phase I clinical trial of participants with advanced Parkinson's disease (PD). Convection-enhanced delivery of AAV2-GDNF with a surrogate imaging tracer (gadoteridol) was used to track infusate distribution during real-time intraoperative magnetic resonance imaging (iMRI). Pre-, intra-, and serial postoperative (up to 5 years after infusion) MRI were analyzed in 13 participants with PD treated with bilateral putaminal co-infusions (52 infusions in total) of AAV2-GDNF and gadoteridol (infusion volume, 450 mL per putamen). Real-time iMRI confirmed infusion cannula placement, anatomic quantification of volumetric perfusion within the putamen, and direct visualization of off-target leakage or cannula reflux (which permitted corresponding infusion rate/cannula adjustments). Serial post-treatment MRI assessment (n = 13) demonstrated no evidence of cerebral parenchyma toxicity in the corresponding regions of AAV2-GDNF and gadoteridol co-infusion or surrounding regions over long-term follow-up. Direct confirmation of key intraoperative safety and efficacy parameters underscores the safety and tissue targeting value of real-time imaging with co-infused gadoteridol and putative therapeutic agents (i.e., AAV2-GDNF). This delivery-imaging platform enhances safety, permits delivery personalization, improves therapeutic distribution, and facilitates assessment of efficacy and dosing effect.
Tongue Telangiectasias in Systemic Sclerosis
Authors: Takeshi Zoshima, Mitsuhiro Kawano
Journal: New England Journal of Medicine (2022)

A 61-year-old woman with primary biliary cholangitis and Raynaud’s phenomenon was referred to the rheumatology clinic. Tongue telangiectasias, puffy fingers, and nailfold capillary hemorrhage were present.
Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling
Authors: Nofar Rosenberg, Matthias Van Haele, Tali Lanton, Neta Brashi, Zohar Bromberg, Hanan Adler, Hilla Giladi, Amnon Peled, Daniel S. Goldenberg, Jonathan H. Axelrod, Alina Simerzin, Chofit Chai, Mor Paldor, Auerlia Markezana, Dayana Yaish, Zohar Shemulian, Dvora Gross, Shanny Barnoy, Maytal Gefen, Osher Amran, Sofie Claerhout, Mirian Fernández-Vaquero, María García-Beccaria, Danijela Heide, Michal Shoshkes-Carmel, Dirk Schmidt Arras, Sharona Elgavish, Yuval Nevo, Hadar Benyamini, Janina E.E. Tirnitz-Parker, Aranzazu Sanchez, Blanca Herrera, Rifaat Safadi, Klaus H. Kaestner, Stefan Rose-John, Tania Roskams, Mathias Heikenwalder, Eithan Galun
Journal: Journal of Hepatology (2022)
KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells
Authors: Jun Chen, Tao-Tao Tang, Jing-Yuan Cao, Zuo-Lin Li, Xin Zhong, Yi Wen, An-Ran Shen, Bi-Cheng Liu, Lin-Li Lv
Journal: Molecular Therapy (2022)

Tubular epithelial cells (TECs) exposed to hypoxia incite tubulointerstitial inflammation (TII), while the exact mechanism is unclear. In this study, we identified that hypoxia evoked tubule injury as evidenced by tubular hypoxia-inducible factor-1α and kidney injury molecule-1 (KIM-1) expression and that renal small extracellular vesicle (sEV) production was increased with the development of TII after ischemia-reperfusion injury (IRI). Intriguingly, KIM-1-positive tubules were surrounded by macrophages and co-localized with sEVs. In vitro, KIM-1 expression and sEV release were increased in hypoxic TECs and the hypoxia-induced inflammatory response was ameliorated when KIM-1 or Rab27a, a master regulator of sEV secretion, was silenced. Furthermore, KIM-1 was identified to mediate hypoxic TEC-derived sEV (Hypo-sEV) uptake by TECs. Phosphatidylserine (PS), a ligand of KIM-1, was present in Hypo-sEVs as detected by nanoflow cytometry. Correspondingly, the inflammatory response induced by exogenous Hypo-sEVs was attenuated when KIM-1 was knocked down. In vivo, exogenous-applied Hypo-sEVs localized to KIM-1-positive tubules and exacerbated TII in IRI mice. Our study demonstrated that KIM-1 expressed by injured tubules mediated sEV uptake via recognizing PS, which participated in the amplification of tubule inflammation induced by hypoxia, leading to the development of TII in ischemic acute kidney injury.
Relationship Between Unrecognized Myocardial Infarction and Underlying Coronary Plaque Characteristics on Optical Coherence Tomography
Authors: Tomoyo Sugiyama, Yoshihisa Kanaji, Masahiro Hoshino, Masahiro Hada, Toru Misawa, Tatsuhiro Nagamine, Yun Teng, Kazuki Matsuda, Kodai Sayama, Makoto Araki, Eisuke Usui, Tadashi Murai, Tetsumin Lee, Taishi Yonetsu, Tetsuo Sasano, Tsunekazu Kakuta
Journal: JACC. Cardiovascular imaging (2022)
Coronary Microvascular Health in Patients With Prior COVID-19 Infection
Authors: Ahmed Ibrahim Ahmed, Jean Michel Saad, Yushui Han, Fares Alahdab, Maan Malahfji, Faisal Nabi, John J. Mahmarian, John P. Cooke, William A. Zoghbi, Mouaz H. Al-Mallah
Journal: JACC. Cardiovascular imaging (2022)
Biodegradable ring-shaped implantable device for intravesical therapy of bladder disorders
Authors: Hyunjoon Kim, Seung Ho Lee, Adam Wentworth, Sahab Babaee, Kaitlyn Wong, Joy E. Collins, Jacqueline Chu, Keiko Ishida, Johannes Kuosmanen, Joshua Jenkins, Kaitlyn Hess, Aaron Lopes, Joshua Morimoto, Qianqian Wan, Shaunak V. Potdar, Ronan McNally, Caitlynn Tov, Na Yoon Kim, Alison Hayward, Daniel Wollin, Robert Langer, Giovanni Traverso
Journal: Biomaterials (2022)
Development and Validation of a Diagnostic Echocardiographic Mass Score in the Approach to Cardiac Masses
Authors: Pasquale Paolisso, Alberto Foà, Ilenia Magnani, Luca Bergamaschi, Maddalena Graziosi, Francesco Angeli, Chiara Chiti, Michele Fabrizio, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Emanuele Gallinoro, Elisa Maietti, Paola Rucci, Elena Biagini, Anna Vittoria Mattioli, Nazzareno Galiè, Carmine Pizzi
Journal: JACC. Cardiovascular imaging (2022)